Recent studies highlight a novel mechanism by which DCs utilize IgE-FcεRI interactions for cross-presentation of tumor antigens, activating cytotoxic CD8+ T lymphocytes (CTLs) even at low antigen doses. Here, IGHE is linked to neoplasm.